Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

as well as advancing other indications in rare cardiovascular conditions requiring chronic anticoagulation; playing a critical role in driving the late-stage clinical development of tecarfarin and ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

as well as advancing other indications in rare cardiovascular conditions requiring chronic anticoagulation; playing a critical role in driving the late-stage clinical development of tecarfarin and the ...

webs and a mosaic perfusion pattern should raise suspicion of chronic rather than acute PE. Suggested approach: Patients with a very low or low PESI score may be offered early discharge and outpatient ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Feb. 5, 2025 — Could the key to easing anxiety be hidden in our gut? Scientists have discovered a crucial connection between gut microbes and anxiety-related behavior. Their research suggests ...

Global Personalized Medicine Market size is expected to be worth around USD 1,103.6 Bn by 2032 from USD 553.8 Bn in 2023, growing at a CAGR of 8.2% ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

I look forward to advancing the late-stage clinical development of tecarfarin and bringing forward the first innovation in vitamin K-targeted anticoagulation in 70 years. This product could have a ...